Risk of Recalls and Discontinued Sales Due to Post-Marketing Adverse Drug Reactions and Quality Issues
First written in FY2016. 11 of 12 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2020RestatedAnnual report
「Unexpected adverse reactions may occur after launch. In such cases, the Company may be forced to recall the product or discontinue its sale, making it difficult to continue selling the Company's active pharmaceutical ingredients and other products, which could materially affect its future operating results.」
The Company continues to disclose the risk that post-launch adverse reactions and quality issues may affect recalls, discontinuation of sales and active pharmaceutical ingredient sales. - FY2019RestatedAnnual report
「Unexpected adverse reactions may occur after launch. In such cases, the Company may be forced to recall the product or discontinue its sale, making it difficult to continue selling the Company's active pharmaceutical ingredients and other products, which could materially affect its future operating results.」
The Company continues to disclose the risk that post-launch adverse reactions and quality issues may affect recalls, discontinuation of sales and active pharmaceutical ingredient sales. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2018RestatedAnnual report
「Unexpected adverse reactions may occur after launch. In such cases, the Company may be forced to recall the product or discontinue its sale, making it difficult to continue selling the Company's active pharmaceutical ingredients and other products, which could materially affect its future operating results.」
The Company continues to disclose the risk that post-launch adverse reactions and quality issues may affect recalls, discontinuation of sales and active pharmaceutical ingredient sales. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2017RestatedAnnual report
「Unexpected adverse reactions may occur after launch. In such cases, the Company may be forced to recall the product or discontinue its sale, making it difficult to continue selling the Company's active pharmaceutical ingredients and other products, which could materially affect its future operating results.」
The Company continues to disclose the risk that post-launch adverse reactions and quality issues may lead to recalls, discontinuation of sales and an impact on active pharmaceutical ingredient sales. - FY2017-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2017-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company discloses that there has been no new occurrence or material change in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2017-Q1RestatedAnnual report
「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company discloses that there have been no material changes in the risk of recalls and discontinuation of sales due to post-launch adverse reactions and quality issues. - FY2016First statedAnnual report
「Unexpected adverse reactions may occur after launch. In such cases, the Company may be forced to recall the product or discontinue its sale, making it difficult to continue selling the Company's active pharmaceutical ingredients and other products, which could materially affect its future operating results.」
This indicates that, even when the Company does not sell products directly, the quality and safety of products supplied by its partners may affect sales of active pharmaceutical ingredients and operating results.